MEDICINOVA INITIATES PHASE II TRIAL FOR MN-221

摘要

MediciNova,Inc.,San Diego,Calif.,a biopharmaceutical company that is publicly traded on NASDAQ (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875),has announced the initiation of the Phase II clinical program to determine the safety and efficacy of MN-221,its novel intravenous product candidate for status asthmaticus.Status asthmaticus is an acute,long-lasting and severe asthma episode that does not respond to initial standard treatments and is potentially fatal.